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Abstract
Background: Our aim was to assess the efficacy of thoracic epidural anesthesia (EA) followed by postoperative
epidural infusion (EI) and patient-controlled epidural analgesia (PCEA) with ropivacaine/fentanyl in off-pump
coronary artery bypass grafting (OPCAB).
Methods: In a prospective study, 93 patients were scheduled for OPCAB under propofol/fentanyl anesthesia and
randomized to three postoperative analgesia regimens aiming at a visual analog scale (VAS) score < 30 mm at rest.
The control group (n = 31) received intravenous fentanyl 10 μg/ml postoperatively 3-8 mL/h. After placement of
an epidural catheter at the level of Th2-Th4 before OPCAB, a thoracic EI group (n = 31) received EA intraoperatively
with ropivacaine 0.75% 1 mg/kg and fentanyl 1 μg/kg followed by continuous EI of ropivacaine 0.2% 3-8 mL/h and
fentanyl 2 μg/mL postoperatively. The PCEA group (n = 31), in addition to EA and EI, received PCEA (ropivacaine/
fentanyl bolus 1 mL, lock-out interval 12 min) postoperatively. Hemodynamics and blood gases were measured
throughout 24 h after OPCAB.
Results: During OPCAB, EA decreased arterial pressure transiently, counteracted changes in global ejection fraction
and accumulation of extravascular lung water, and reduced the consumption of propofol by 15%, fentanyl by 50%
and nitroglycerin by a 7-fold, but increased the requirements in colloids and vasopressors by 2- and 3-fold,
respectively (P < 0.05). After OPCAB, PCEA increased PaO2/FiO2 at 18 h and decreased the duration of mechanical
ventilation by 32% compared with the control group (P < 0.05).
Conclusions: In OPCAB, EA with ropivacaine/fentanyl decreases arterial pressure transiently, optimizes myocardial
performance and influences the perioperative fluid and vasoactive therapy. Postoperative EI combined with PCEA
improves lung function and reduces time to extubation.
Trial Registration: NCT01384175
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Background
Coronary artery bypass grafting (CABG) is one of the
most common cardiosurgical interventions. In many
institutions, CABG is performed without cardiopulmon-
ary bypass (CPB), a modification which is commonly
referred to as off-pump coronary artery bypass grafting
(OPCAB) [1-4]. The off-pump technique enables coron-
ary revascularization on the beating heart, thereby redu-
cing the risk of complications associated with CPB.
However, OPCAB can be accompanied by hemodynamic
alterations, postoperative pain, and respiratory dysfunc-
tion, requiring thorough monitoring and perioperative
care [3-6].
In cardiosurgical patients, high thoracic epidural
anesthesia (EA) with local anesthetics and opioids can
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perioperative complications [6-8]. However, the use of
EA in coronary surgery is controversial, and it is still
unclear whether EA influences lung fluid balance, cardi-
opulmonary function and clinical outcome in OPCAB.
Thus, the method requires further evaluation and its
potential benefits in coronary patients should be
weighed against its risks [8,9].
Patient-controlled epidural analgesia (PCEA) is an
attractive technique for postoperative pain relief. How-
ever, in OPCAB the role of PCEA with administration
of a ropivacaine/fentanyl mixture via a thoracic epidural
catheter remains unsettled.
We hypothesized that after OPCAB, thoracic epidural
analgesia with ropivacaine and fentanyl aiming at a
visual analog scale (VAS) score < 30 mm will be asso-
ciated with improved cardiopulmonary parameters in
comparison with intravenously administered analgesia. If
the hypothesis is confirmed, we expect that epidural
administration of ropivacaine and fentanyl, including a
patient-controlled mode, might reduce the duration of
mechanical ventilation. Thus, the duration of mechani-
cal ventilation and the changes in cardiopulmonary vari-
ables served as the primary and the secondary study
end-points, respectively. Using these end-points, the aim
of our study was to assess the influence of EA followed
by postoperative PCEA with ropivacaine/fentanyl on
cardiopulmonary function in the perioperative manage-
ment of OPCAB patients.
Methods
Patients
The study protocol and informed consent form were
approved by the Ethics Committee of Northern State
Medical University, Arkhangelsk, Russian Federation.
Written informed consent was obtained from every
patient.
The study was performed in a 900-bed university hos-
pital. During the period from January of 2008 to Sep-
tember of 2009, 93 adult patients with coronary artery
disease, ranked ASA III and scheduled for elective
OPCAB, were enrolled into a prospective randomized
study. Exclusion criteria were age < 18 years, severe
valve dysfunction or peripheral vascular disease, simulta-
neous interventions (carotid endarterectomy, aneurysm
repair, etc.), or transfer to CPB during surgery.
Anesthesia and surgery
All patients received standard premedication with diaze-
pam (Seduxen; Gedeon Richter, Budapest, Hungary).
After establishment of routine hemodynamic monitoring
with ECG including ST segment analysis, blood pres-
sure, and SpO2 measurements, anesthesia was induced
with intravenous midazolam (Dormicum, F. Hoffmann-
La Roche Ltd., Switzerland) 0.07 mg/kg, propofol (Dipri-
van, AstraZeneca, UK) 1 mg/kg, and fentanyl (Fentanyl,
Moscow Endocrine Factory, Russian Federation) 3-5 μg/
kg. Neuromuscular blockade was induced with intrave-
nous pipecuronium (Arduan, Gedeon Richter, Hungary)
0.1 mg/kg and maintained with repeated doses of pipe-
curonium 0.015 mg/kg/h. Anesthesia was maintained
with propofol 3 mg/kg/h from the onset and continuing
with 3-5 mg/kg/h, and fentanyl 2-4 μg/kg/h, aiming at
heart rate within 50-90 beats/min and mean arterial
pressure within 60-80 mm Hg.
Mechanical ventilation in the operating room was per-
formed by using a semi-closed anesthetic circuit (Fabius,
Dräger, Germany) with FiO2 0.5, tidal volume 7-8 mL/
kg, respiratory rate 12-14/min aiming at a PaCO2 of 35-
45 mm Hg, positive end-expiratory pressure 4 cm H2O,
and fresh gas flow of 1 L/min.
Fluid therapy included infusion of Ringer’s lactate at
rates of 6-7 mL/kg/h prior to and during anesthesia and
2-3 mL/kg/h during the first 6 h postoperatively. In
cases of hypovolemia, diagnosed by volumetric hemody-
namic monitoring (Figure 1), we administered Gelofusin
(Braun, Germany) 6-8 mL/kg over 30 min. A transfusion
trigger was hemoglobin level < 8 g/dL.
All patients were operated by the same team of sur-
geons using midline sternotomy, and Acrobat SUV OM-
9000S (Guidant, Santa Clara, USA) device for stabiliza-
tion of the heart during revascularization. After pericar-
diotomy, we administered heparin 100 Units/kg aiming
at maintenance of activated clotting time > 250 sec dur-
ing revascularization.
Randomization and protocol
The patients were randomized to three groups using the
envelope method. All groups received lornoxicam (Xefo-
cam, Nycomed, Austria) 8 mg IV before OPCAB and
every 12 h during two postoperative days.
Figure 2 displays a flowchart of the study groups. The
control group (n = 31) had no epidural catheter and
received fentanyl 10 μg/ml intravenously at a rate of 3-8
mL/h postoperatively.
In two other groups, an epidural catheter (Perifix 16G,
Braun, Germany) was inserted at Th2-Th4 level before
induction of anesthesia. The epidural space was identi-
fied by the loss-of-resistance technique; 3 to 4 cm of
the catheter was inserted into the epidural space fol-
l o w e db ya d m i n i s t r a t i o no fat e s td o s eo f1m Lo f2 %
lidocaine.
After placement of the epidural catheter and induction
of anesthesia, the thoracic epidural infusion (EI) group
(n = 31) received EA with ropivacaine (Naropin, Astra-
Zeneca, UK) 0.75% 1 mg/kg and fentanyl 1 μg/kg fol-
lowed by postoperative continuous EI of ropivacaine
0.2% and fentanyl 2 μg/mL at a rate of 3-8 mL/h.
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perative therapy as the EI group but, at variance, this
was combined with postoperative PCEA using a pro-
grammable infusion pump (Graseby 3300, UK) with
ropivacaine/fentanyl bolus 1 mL, which could be admi-
nistered on the patients discretion with a lock-out inter-
val of 12 min. The patients started to use PCEA after
recovery from anesthesia.
The postoperative analgesia was administered by the
attending physician, who adjusted the infusion rate of
fentanyl in the control group and ropivacaine/fentanyl
in the EI groups beginning from 3 mL/h and aiming at
a VAS score of < 30 mm at rest. All patients received
aspirin postoperatively at a daily dose of 75 mg per os.
Measurements
The femoral artery was catheterized with a 5F arterial
thermodilution catheter (Pulsiocath PV2015L20, Pulsion,
Germany), which was connected to a LifeScope (Nihon
Kohden, Japan) and a PiCCOplus (Pulsion Medical Sys-
tems, Germany) monitor for thermodilution measure-
ments and continuous hemodynamic monitoring. After
induction of anesthesia, an 8.5F central venous catheter
was inserted into the internal jugular vein. The
Figure 1 Flowchart showing algorithm for hemodynamic monitoring and perioperative management. MAP: mean arterial pressure; HR:
heart rate; GEDVI: global end-diastolic volume index; CI: cardiac index; SVRI: systemic vascular resistance index. During anesthesia, this algorithm
was used to correct HR and MAP only if the doses of propofol 3-5 mg/kg/h and fentanyl 2-4 μg/kg/h were unable to maintain HR within 50-90
beats/min and MAP within 60-80 mm Hg. For perioperative management, we used the following doses of intravenous agents: ephedrine 5-10
mg, phenylephrine 0, 05-1 mg, nitroglycerine 0, 3-3 mg/h and furosemide 10-20 mg.
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(HR), mean arterial pressure (MAP), and central venous
pressure (CVP), as well as global end-diastolic volume
index (GEDVI), cardiac index (CI), extravascular lung
water index (EVLWI), cardiac function index (CFI), glo-
bal ejection fraction (GEF), left ventricle contractility
index (dPmax), and systemic vascular resistance index
(SVRI).
The hemodynamic parameters were registered after
induction of anesthesia, at the restraint of the heart by
using the stabilizing devices, at 5 min after restoration
of blood flow via t h ec o r o n a r yg r a f t s ,a tt h ee n do fs u r -
gery, and at 2, 6, 12, 18, and 24 h postoperatively. These
time-points were selected for goal-directed hemody-
namic adjustments (Figure 1).
Blood gases and plasma lactate concentration were
measured after induction of anesthesia, at the end of
surgery, and at 2, 6, 12, 18, and 24 h postoperatively
using ABL800Flex (Radiometer, Denmark). Plasma con-
centrations of cortisol and troponin-T were measured
before surgery and at 6 and 18 h postoperatively (Roche
Diagnostics GmbH, Germany).
The severity of postoperative pain at rest and during
coughing was assessed by the attending physician with
VAS score at 6, 12, 18, and 24 h after OPCAB. The
level of sedation was also evaluated by the attending
physician by means of the Ramsay’s score. In addition,
we recorded the drug consumption, the perioperative
fluid balance and administration of fluids, inotropes and
vasoactive drugs, perioperative adverse effects, duration
of surgery and postoperative mechanical ventilation,
lengths of postoperative ICU and hospital stay, and the
mortality rate at Day 28.
Extubation criteria were the following: a cooperative,
alert patient; adequate muscular tone; SpO2 >9 5 %w i t h
FiO2 0.5; PaCO2 <4 5m mH g ;s t a b l eh e m o d y n a m i c s
without inotrope/vasopressor support; absence of
arrhythmias; and body temperature > 35°C. Temporary
pacing was not regarded as a contraindication to
extubation.
The patients were discharged from hospital if they
satisfied the following criteria: hemodynamic stability,
independence in ambulation and feeding, afebrile with
clean wound and no obvious infections, normal voiding
and bowel movements, pain control on oral medica-
tions, and exercise tolerance. The doctor responsible for
discharge from the hospital was unaware of the study
groups.
Statistical analysis
For data collection and analysis, we used SPSS software
(version 14.0; SPSS Inc., Chicago, IL, USA). Calculation
of sample size was based on initial observations (10
cases in each group) and the hypothesis that postopera-
tive PCEA will shorten the time to tracheal extubation
by 90 min compared with the control group. In order to
find a statistically significant difference with a of 0.05
and power of 0.8, a sample size of 30 patients in each
group proved to be sufficient. The normality of the data
distribution was assessed using the Shapiro-Wilk test. In
case of normal distribution, we used ANOVA and post
hoc Dunnet test for comparison among the groups and
repeated measures ANOVA followed by test of contrasts
for intragroup comparisons. Non-parametrically distrib-
uted data were assessed by Friedman test followed by
Wilcoxon test, respectively. The quantitative values are
Figure 2 Flowchart of the study groups. EI: epidural infusion group; PCEA: patient-controlled epidural analgesia group.
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Page 4 of 10expressed as mean ± SD and median (25
th-75
th percen-
tiles) in accordance with data distribution. The discrete
data were analyzed by two-sided chi-square test and
expressed as patient number or percentage. For all tests,
a P-value < 0.05 was considered as significant.
Results
As shown in Table 1, we found no significant differ-
ences among the groups concerning demographic data,
including co-morbidities and preoperative ejection frac-
tion. Three patients (one patient in each group) who
became hemodynamically unstable during CABG were
t r a n s f e r r e dt oC P Ba n de x c l u d e df r o mf u r t h e ra n a l y s i s
(Figure 2). One of these patients (belonging to the EI
group) required re-operation and died because of post-
operative bleeding from the aorta. All the other patients
survived to Day 28 and were discharged from hospital.
Duration of surgery, as well as of ICU and hospital
stays, did not differ among the groups. The duration of
mechanical ventilation was reduced by 32% in the PCEA
group (P = 0.04) and tended to decrease in the EI group
(P = 0.14) compared with the control group (Table 1).
Table 2 displays changes in hemodynamics. In the
groups receiving EA, MAP decreased transiently by 10-
15% during OPCAB (P < 0.05), but rose postoperatively
without intergroup differences. After induction of
anesthesia, all groups demonstrated reduced HR, CI,
CFI, dPmax and GEF, and increased SVRI as compared
to normal values. Perioperatively, HR, CI, and CFI rose
in all groups whereas SVRI declined (P <0 . 0 5 ) .C o m -
pared to baseline, CVP increased significantly at the
restraint of the heart and then decreased after OPCAB
in all groups (P < 0.05). Global end-diastolic volume
index did not change significantly. In the EI and the
PCEA groups, dPmax increased postoperatively by 70-
85% (P < 0.05). By contrast, in the control group GEF
decreased by 10-15% during OPCAB, and EVLWI rose
by 22% during the restraint of the heart (P < 0.05).
Table 3 demonstrates blood gases and biochemical
variables. In all groups, pH declined intraoperatively and
during 6 h postoperatively, but increased significantly at
24 h in the groups receiving epidural analgesia. In paral-
lel, PaCO2 decreased from intragroup baseline during
12-24 h in the EI group and during 18-24 h in the
PCEA group but without differences with control group
where PaCO2 also reduced at 24 h. At 18 h, PaO2/FiO2
was higher in the PCEA group (P = 0.03 compared with
controls). Plasma concentrations of lactate and glucose
rose postoperatively in all groups; however, in the PCEA
group lactate fell by 33% compared with the control
group (P = 0.04) at 18 h. After OPCAB, plasma concen-
trations of cortisol and troponin T increased without
intergroup differences.
The VAS scores were within 20 mm at rest and 30
mm during coughing in all groups without intergroup
differences excluding 12 h when VAS score was signifi-
cantly lower in the PCEA group as compared to con-
trols (Table 4). The level of postoperative sedation did
not differ among the groups.
Table 5 shows that during OPCAB, EA reduced the
consumption of propofol by 15% and fentanyl by 50% (P
< 0.05). The postoperative requirement of ropivacaine
increased by 20% in the PCEA group as compared with
the EI group (P=0.03). In both EA groups, the require-
ment of nitroglycerin decreased by a 7-fold intraopera-
t i v e l ya n db ya2 . 5 - f o l da f t e rO P C A B( P <0 . 0 5 ) .
Intraoperative inotropes/vasopressors were administered
more frequently in the EA groups as compared with the
control group (43% vs. 13%, respectively; P = 0.02). Col-
loids also were given more frequently in the patients
receiving EA (75% vs. 37%, P = 0.01). After OPCAB, the
incidence of colloid administration was higher in the EI
group compared with the other groups (P <0 . 0 5 ) .
Intraoperative fluid balance increased by 21% in the EA
groups (P < 0.05). There were no significant differences
in blood loss, urine output, administration of crystalloids
Table 1 Main characteristics of patients undergoing OPCAB
Characteristic Groups
Control
(n = 30)
EI
(n = 30)
PCEA
(n = 30)
Age, yrs 58.6 ± 9.1 54.5 ± 8.2 53.6 ± 7.0
Gender, males/females, % 73/27 90/10 90/10
Preoperative ejection fraction 0.58 ± 0.10 0.58 ± 0.08 0.59 ± 0.09
Duration of surgery, min 174 ± 38 149 ± 36 155 ± 40
Duration of mechanical ventilation, min 358 (266-455) 300 (180-385) 245 (199-345)*
Postoperative ICU stay, h 59 ± 29 62 ± 28 59 ± 25
Duration of postoperative hospital stay, days 16.0 (14.8-20.3) 15.0 (14.0-18.5) 15.0 (14.0-18.3)
Data are presented as mean ± SD or median (25
th-75
th percentiles).
* P < 0.05 compared with the control group.
Control, control group; EI, epidural infusion group; PCEA, patient controlled epidural analgesia group.
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Page 5 of 10Table 2 Hemodynamic parameters in patients undergoing OPCAB
Characteristic Group Intraoperative period Postoperative period
After induction
of anesthesia
Fixation of
the heart
5 min
after
start
flow
End of
operation
2 hours 6 hours 12 hours 18 hours 24 hours
Control 79.9 ± 13.5 76.9 ± 15.6 74.6 ± 14.3 80.2 ± 10.4 89.9 ± 15.3
+ 87.6 ± 12.7
+ 82.5 ± 14.8
# 80.1 ± 13.1 80.1 ± 13.1
MAP, mm Hg EI 72.8 ± 8.37 67.8 ± 13.5
+ 72.6 ± 11.8 74.2 ± 12.6 86.1 ± 17.6
+ 81.2 ± 14.9
+ 72.0 ± 12.4 76.1 ± 12.4 75.6 ± 11.4
PCEA 79.4 ± 13.6 67.5 ± 12.1
+ 74.7 ± 12.7 72.6 ± 11.4
+ 89.6 ± 14.9
+ 89.4 ± 17.5
+ 83.7 ± 17.3
# 79.1 ± 17.9 82.3 ± 17.0
Control 50.0 (42.3-59.8) 59.5 (51.3-64.8)
+ 62.5 (50.5-70.5)
#+ 61.0 (55.3-74.5)
#+ 77.5 (71.0-85.0)
+ 87.5 (77.5-98.0)
+ 87.0 (80.3-101.0)
#+ 82.5 (75.0-96.8)
+ 83.5 (77.0-94.5)
+
HR, 1/min EI 52.0 (43.3-59.8) 51.5 (44.3-63.8) 54.5 (48.3-62.8) 56.0 (48.3-66.0) 66.5 (56.8-84.0)
+ 85.0 (75.5-88.8)
+ 79.5 (75.3-92.0)
+ 81.0 (73.0-89.8)
+ 80.0 (74.8-88.8)
+
PCEA 54.0 (48.5-64.0) 55.0 (49.0-63.0) 58.0 (54.0-65.0) 61.0 (55.0-66.5) 71.0 (64.0-86.5)
+ 91.0 (82.0-105.0)
+ 89.0 (83.0-94.0)
#+ 86.0 (78.5-91.5)
+ 86.0 (80.5-93.5)
+
Control 2.20 ± 0.42 2.43 ± 0.59 2.96 ± 1.23
+ 2.70 ± 0.80 3.27 ± 0.74
+ 3.55 ± 0.83
+ 3.69 ± 0.78
+ 3.39 ± 0.38 3.46 ± 0.42
+
CI, l/min/m
2 EI 2.20 ± 0.44 1.97 ± 0.51 2.55 ± 0.33
+ 2.57 ± 0.55
+ 3.12 ± 0.69
+ 3.43 ± 0.59
+ 3.43 ± 0.53
+ 3.34 ± 0.50 3.32 ± 0.44
+
PCEA 2.15 ± 0.46 1.89 ± 0.51 2.81 ± 0.75
+ 2.58 ± 0.80 3.27 ± 0.87
+ 3.79 ± 0.63
+ 3.46 ± 0.49
+ 3.08 ± 0.44 3.40 ± 0.46
+
Control 3.47 ± 1.18 3.14 ± 1.04 3.88 ± 1.42 3.79 ± 1.24 4.71 ± 1.83
+ 5.01 ± 1.73
+ 5.56 ± 1.92
+ 4.96 ± 1.19
+ 4.98 ± 1.11
+
CFI, 1/min EI 3.42 ± 0.77 3.03 ± 0.65
+ 3.69 ± 0.69 3.65 ± 0.87 4.68 ± 0.92
+ 5.25 ± 0.76
+ 5.23 ± 1.22
+ 5.13 ± 1.14
+ 4.95 ± 1.29
+
PCEA 3.32 ± 0.68 3.08 ± 0.66 3.97 ± 1.04
+ 3.88 ± 1.16
+ 4.47 ± 1.21
+ 5.33 ± 1.56
+ 4.87 ± 1.22
+ 4.28 ± 1.07
+ 4.30 ± 1.14
+
Control 2709 ± 500 2484 ± 773 2256 ± 725 2228 ± 568
+ 2150 ± 637 1967 ± 763
+ 1647 ± 648
+ 1731 ± 378
+ 1790 ± 428
+
SVRI, dyne’sec’cm
-5’m
-2 EI 2458 ± 707 2120 ± 600 1933 ± 287
+ 1953 ± 290 1993 ± 482 2035 ± 491
+ 1677 ± 456
+ 1846 ± 277
+ 1788 ± 329
+
PCEA 2912 ± 970 2299 ± 791 2059 ± 892 2112 ± 733
+ 2223 ± 554 2086 ± 405 2123 ± 487
+ 2205 ± 623*
+ 2078 ± 604
+
Control 11.3 ± 3.6 14.0 ± 4.0
#+ 11.8 ± 3.7
# 12.7 ± 3.5
#+ 7.6 ± 3.7
+ 5.9 ± 3.1
+ 5.0 ± 4.0
+ 4.6 ± 4.2
+ 5.8 ± 4.6
+
CVP, mm Hg EI 12.5 ± 3.1 16.8 ± 3.2
+ 14.4 ± 2.5
+ 14.9 ± 2.3
+ 8.9 ± 3.3
+ 7.2 ± 4.8
+ 6.3 ± 4.2
+ 5.4 ± 5.3
+ 4.9 ± 3.3
+
PCEA 11.4 ± 2.67 15.0 ± 3.8
+ 13.0 ± 3.0
+ 13.4 ± 2.8
+ 8.3 ± 4.3
+ 4.3 ± 3.5
#+ 4.1 ± 3.3
+ 4.6 ± 4.0
+ 5.4 ± 3.8
+
Control 689 ± 243 797 ± 227 765 ± 168 711 ± 117 729 ± 169 724 ± 165 695 ± 188 715 ± 199 710 ± 145
GEDVI, ml/m
2 EI 674 ± 215 661 ± 250 696 ± 153 704 ± 251 680 ± 149 659 ± 106 660 ± 125 661 ± 107 682 ± 115
PCEA 653 ± 143 646 ± 159 722 ± 116 665 ± 146 683 ± 251 728 ± 139 728 ± 133 720 ± 125 799 ± 148
Control 697 ± 116 537 ± 169 567 ± 142 565 ± 145 803 ± 412 773 ± 307 770 ± 255 744 ± 412 915 ± 339
dPmax, mm Hg/sec EI 542 ± 136 479 ± 150 552 ± 141 567 ± 201 803 ± 412
+ 849 ± 288
+ 880 ± 293
+ 1015 ± 421
+ 997 ± 353
+
PCEA 561 ± 203 457 ± 159 536 ± 179 578 ± 219 843 ± 263
+ 813 ± 177
+ 909 ± 284
+ 877 ± 243
+ 857 ± 195
+
Control 24.6 ± 6.1 21.0 ± 6.6
+ 22.2 ± 7.0 22.0 ± 5.6
+ 22.3 ± 5.8 22.3 ± 4.7 24.0 ± 6.3 22.0 ± 5.4 21.7 ± 5.3
GEF, % EI 26.2 ± 7.30 23.5 ± 5.4 26.1 ± 6.3 26.0 ± 7.0 26.7 ± 7.7 22.6 ± 5.0 24.2 ± 6.1 24.0 ± 5.7 22.9 ± 5.5
PCEA 21.8 ± 7.2 21.2 ± 6.1 24.6 ± 6.2
+ 23.8 ± 6.5 23.9 ± 5.1 22.8 ± 5.7 21.6 ± 6.3 19.0 ± 5.1 19.6 ± 4.8
Control 9.0 (7.0-10.0) 11.0 (8.0-14.0)
+ 9.0 (8.0-11.0) 10.0 (7.0-11.0) 8.0 (5.0-12.0) 8.0 (6.0-11.0) 10.0 (6.0-11.0) 8.0 (5.0-14.0) 9.0 (8.0-13.0)
EVLWI, ml/kg EI 9.0 (7.0-9.5) 8.5 (6.8-10.5) 9.0 (7.0-10.3) 8.0 (6.8-10.0) 7.5 (6.0-11.8) 6.5 (6.0-10.3) 6.0 (5.8-7.3)
+ 7.00 (6.8-8.8) 7.5 (6.0-9.3)
PCEA 8.0 (6.3-9.8) 9.5 (7.0-11.0) 8.0 (7.3-11.8) 8.0 (7.0-10.5) 8.0 (7.0-12.8) 6.5 (6.0-8.0) 7.0 (5.3-8.8) 7.5 (6.0-9.8) 7.5 (7.0-10.8)
Data are presented as mean ± SD or median (25
th-75
th percentiles).
* P < 0.05 compared with the control group;
# P < 0.05 compared with the EI group;
+ P < 0.05 compared with baseline (after induction of anesthesia).
Control, control group; EI, epidural infusion group; PCEA, patient controlled epidural analgesia group; MAP, mean arterial pressure; HR, heart rate; CI, cardiac index; CFI, cardiac function index; SVRI, systemic vascular
resistance index; CVP, central venous pressure; GEDVI, global end-diastolic volume index; dPmax, left ventricle contractility index; GEF, global ejection fraction; EVLWI, extravascular lung water index.
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0and adverse events (not shown). There were no compli-
cations related to EA.
Discussion
The present study demonstrates that EA with ropiva-
caine/fentanyl causes a moderate decrease in arterial
pressure and prevents reduction of GEF and lung fluid
accumulation during OPCAB. The epidural administra-
tion of ropivacaine and fentanyl reduces the require-
ment of nitroglycerin and intravenous agents for
anesthesia and analgesia, but requires more frequent
perioperative therapy with colloids and inotropes/
vasopressors. Postoperatively, EI provides adequate
analgesia and improves left ventricle myocardial con-
tractility. Moreover, EI combined with PCA is associated
with mild hyperventilation, transient improvement of
oxygenation and tissue perfusion and decreased duration
of mechanical ventilation after OPCAB in comparison
with the control group.
The postoperative improvement of lung function
observed in the PCEA group was accompanied by
reduced time to tracheal extubation, but the durations
of ICU and hospital stays did not differ significantly.
These results are in accordance with other studies of EA
Table 3 Laboratory parameters in patients undergoing OPCAB
Characteristic Group Period
After induction of anesthesia End of
Operation
2 hours 6 hours 12 hours 18 hours 24 hours
Control 7.39 ± 0.04 7.34 ± 0.05
+ 7.30 ± 0.04
+ 7.33 ± 0.03
+ 7.36 ± 0.03
+ 7.39 ± 0.03 7.40 ± 0.06
pH EI 7.37 ± 0.03 7.34 ± 0.04
+ 7.30 ± 0.06
+ 7.34 ± 0.04
+ 7.38 ± 0.03
+ 7.39 ± 0.03
+ 7.41 ± 0.03
+
PCEA 7.38 ± 0.03 7.34 ± 0.05
+ 7.30 ± 0.04
+ 7.35 ± 0.04
+ 7.37 ± 0.04 7.40 ± 0.03 7.40 ± 0.03
+
Control 38.2 ± 3.49 39.0 ± 5.56 41.1 ± 5.05 39.0 ± 4.21 38.0 ± 5.10 36.8 ± 4.14 33.7 ± 4.13
+
PaCO2, mm Hg EI 40.1 ± 4.41 39.4 ± 5.16 42.1 ± 6.90 38.5 ± 4.93 35.7 ± 4.82
+ 36.1 ± 3.61
+ 34.2 ± 2.86
+
PCEA 39.2 ± 3.77 39.2 ± 5.36 42.1 ± 4.34 37.8 ± 3.29 36.7 ± 3.97 34.5 ± 3.73
+ 33.9 ± 4.38
+
Control 287 ± 100 243 ± 108 275 ± 73 282 ± 80 273 ± 76 272 ± 139 302 ± 98
PaO2/FiO2, mm Hg EI 323 ± 110 272 ± 93 292 ± 97 296 ± 71 290 ± 87 281 ± 89 282 ± 110
PCEA 336 ± 104 257 ± 83 300 ± 71 303 ± 103 298 ± 91 340 ± 129* 347 ± 124
Control 1.00 ± 0.28 1.28 ± 0.63 1.50 ± 0.74
+ 1.75 ± 0.76
+ 1.74 ± 0.87
+ 1.80 ± 0.58
+ 1.50 ± 0.40
+
Lactate, mmol/l EI 1.07 ± 0.78 1.16 ± 0.36 1.38 ± 0.62 1.50 ± 0.74
+ 1.46 ± 0.81 1.44 ± 0.44 1.20 ± 0.37
PCEA 1.06 ± 0.36 1.09 ± 0.42 1.40 ± 0.80
+ 1.81 ± 0.86
+ 1.70 ± 0.77
+ 1.35 ± 0.44
+* 1.48 ± 0.71
+
Control 5.71 ± 1.51 6.77 ± 2.00
+ 8.01 ± 2.67
+ 8.42 ± 3.15
+ 7.22 ± 2.56
+ 6.17 ± 1.47 6.33 ± 1.36
Glucose, mmol/l EI 5.16 ± 1.40 5.97 ± 1.44 7.28 ± 2.24
+ 6.90 ± 1.84
+ 6.25 ± 1.96
+ 5.64 ± 1.32 6.81 ± 2.34
+
PCEA 5.60 ± 1.48 6.41 ± 2.18
+ 7.68 ± 2.79
+ 7.84 ± 2.64
+ 7.12 ± 1.92
+ 6.13 ± 1.68
+ 6.59 ± 1.52
Control 219 ± 80 - - 984 ± 334
+ - 714 ± 297
+ -
Cortisol, nmol/l EI 296 ± 111 - - 861 ± 366
+ - 618 ± 322
+ -
PCEA 303 ± 108 - - 832 ± 371
+ - 591 ± 223
+ -
Control 0.01 ± 0.00 - - 0.32 ± 0.30
+ - 0.25 ± 0.35 -
Troponin T, ng/ml EI 0.01 ± 0.00 - - 0.20 ± 0.11
+ - 0.10 ± 0.08 -
PCEA 0.01 ± 0.00 - - 0.26 ± 0.20
+ - 0.33 ± 0.52 -
Data are presented as mean ± SD.
*P < 0.05 compared with the control group;
+ P < 0.05 compared with baseline (after induction of anesthesia).
Control, control group; EI, epidural infusion group; PCEA, patient controlled epidural analgesia group.
Table 4 Postoperative pain as assessed by visual analog scale (VAS) in patients undergoing OPCAB
Characteristic Group Time after surgery
6 hours 12 hours 18 hours 24 hours
Control 20 (0-30) 20 (0-35) 20 (0-30) 10 (0-20)
VAS at rest EI 15 (0-30) 10 (0-20) 10 (0-20) 0 (0-20)
PCEA 0 (0-20) 0 (0-10)* 0 (0-18) 0 (0-18)
Control 30 (0-55) 30 (20-50) 30 (20-50) 30 (20-50)
VAS during coughing EI 20 (0-40) 30 (20-40) 30 (10-50) 30 (20-40)
PCEA 20 (10-40) 20 (0-30) 30 (10-40) 20 (20-40)
Data are presented as median (25
th-75
th percentiles). *P < 0.05 compared with the control group.
Control, control group; EI, epidural infusion group; PCEA, patient controlled epidural analgesia group.
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Page 7 of 10in coronary surgery and can be explained by a wide
range of confounding factors that are able to influence
the length of hospitalization [8,10-17]. However, accord-
ing to Sharma et al., the use of epidural analgesia in
obese patients can shorten the ICU stay after OPCAB
[13]. This effect was explained by a reduced incidence
of respiratory complications in this category of high-risk
patients. Earlier hospital discharge after EA for CABG
was also reported by de Vries et al. [18].
After induction of anesthesia, all the groups presented
with myocardial dysfunction and systemic vasoconstric-
tion, as judged by the occurrence of bradycardia,
decreased CI, CFI and dPmax, and increased SVRI. The
restraint of the heart was accompanied by a rise in CVP,
paralleled by a decline in GEF and an increase in EVLW
in the control group. This is typical for OPCAB and can
be explained by “enucleation” of the heart, kinking of
vessels, reduction of venous return, and impairment of
ventricular geometry [1,19]. After OPCAB, we observed
a reduction of systemic vascular tone and a rise in myo-
cardial performance. These changes are consistent with
other investigations of CABG and may result from the
restoration of coronary blood flow and reversal of myo-
cardial depression by goal-directed hemodynamic opti-
mization [1,19,20]. As shown in several previous studies,
volumetric parameters measured by transpulmonary
thermodilution, such as GEDVI, which we used for
hemodynamic optimization, is a more sensitive indicator
of preload compared to CVP and can serve as guidance
for colloid administration [19-24]. Most likely, this
allowed us to maintain normal preload in all groups.
During OPCAB, EA decreased MAP transiently and
partly prevented the decline in GEF as well as lung
water accumulation, which we observed in the control
group. In addition, in contrast to the control group,
postoperative EI prompted a significant increase in
dPmax. Although displaying only statistical intragroup
differences, these changes can be explained by the
hemodynamic effects of epidural blockade, including
afterload reduction, that can lead to improvements in
myocardial performance and pulmonary blood flow
[7,10,25,26]. Recently, similar findings were noticed by
investigators, who used EA in on-pump CABG [25,26].
The changes in hemodynamics observed during and
after OPCAB were accompanied by transient metabolic
acidosis and increased plasma lactate in parallel with
hyperglycemia and rise in cortisol and troponin-T
plasma concentrations in all groups. These data are con-
sistent with results published by other authors and can
be explained by tissue hypoperfusion, inflammation, sur-
gical stress and myocardial damage caused by CABG
[1,14,26,27].
We found that epidural analgesia after OPCAB
resulted in mild hyperventilation. Moreover, the PCEA
with ropivacaine/fentanyl led to transient postoperative
improvement in arterial oxygenation and decreased lac-
tate, possibly due to improvement of pulmonary and
systemic perfusion [28]. In addition to these mechan-
isms, the advantageous respiratory effects of epidural
blockade in cardiac surgery were associated with
reduced incidence of postoperative atelectases and
improved quality of analgesia [15-17,28]. In our study,
epidural anesthesia and analgesia provided adequate
pain control, similar to that observed after administra-
tion of opioids in the control group, as confirmed by
VAS score < 30 mm in both epidural groups; optimal
analgesia was observed after PCEA. Thus, the combined
effects of analgesia, pulmonary vasodilation, prevention
Table 5 Requirements of drugs and volume balance in patients undergoing OPCAB
Characteristic Groups
Control (n = 30) EI (n = 30) PCEA (n = 30)
Propofol during surgery, mg 1200 (988-1400) 1000 (775-1100)* 1100 (900-1200)
Fentanyl during surgery, mg 1.2 (1.1-1.3) 0.6 (0.5-0.7)* 0.6 (0.5-0.9)*
Fentanyl during first 24 hrs after surgery, mg 0.70 (0.50-1.00) 0.27 (0.20-0.30) 0.30 (0.20-0.35)
Ropivacaine during surgery, mg - 75 (75-100) 75 (75-100)
Ropivacaine during first 24 hrs after surgery, mg - 250 (192-300) 300 (200-348)
#
Nitroglycerin during surgery, mg 11.0 (6.7-19.5) 1.0 (0.0-2.3)* 2.2 (0.0-4.0)*
Nitroglycerin during first 24 hrs after surgery, mg 24.0 (16.0-33.5) 10.0 (0.0-15.0)* 9.0 (0.0-18.5)*
Inotropes/vasopressors during surgery, number of patients 5 15* 11
Inotropes/vasopressors during first 24 hrs after surgery, number of patients 0 5 1
Colloids during surgery, number of patients 11 21* 24*
Colloids during first 24 hrs after surgery, number of patients 7 16* 6
#
Fluid balance during surgery, ml 1614 ± 537 1949 ± 475* 1919 ± 354
Data are presented as mean ± SD, median (25
th-75
th percentiles), or number of patients.
* P < 0.05 compared with the control group;
# P < 0.05 compared with the EI group.
Control: control group; EI, epidural infusion group; PCEA, patient controlled epidural analgesia group.
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Page 8 of 10of lung edema and improvement of pulmonary
mechanics might have resulted in a better lung function
in the PCEA group that allowed earlier termination of
respiratory support.
In the present study, the analgesic effect of epidural
administration of ropivacaine and fentanyl reduced the
requirements of intravenously administered fentanyl and
propofol for general anesthesia. The postoperative use
of PCEA led to increased consumption of ropivacaine
but did not influence the incidence of adverse events
after OPCAB, like oversedation, pruritus, nausea, vomit-
ing or arrhythmias. This is consistent with other investi-
gations in this field. By contrast, several authors report
reduced incidence of atrial fibrillation after EA for cor-
onary surgery, probably due to the sympatholythic
action of epidural blockade [11,15,28-30]. Thus, by redu-
cing the requirements in opioids, time to tracheal extu-
bation and number of complications, EA can become
part of a fast-track concept of cardiac anesthesia that is
aimed to achieve cost-savings, and improve clinical out-
come, as suggested by recent workers [31]. Despite sev-
eral beneficial effects of EA, we found increased
requirements for colloids and inotrope/vasopressor sup-
port to maintain targeted hemodynamic values. This led
to increased intraoperative fluid balance that also might
have influenced cardiopulmonary function. In parallel,
thoracic epidural administration of ropivacaine and fen-
tanyl resulted in significant reduction of perioperative
nitroglycerin requirement. These changes can be
explained by vasodilation and redistribution of blood
volume caused by EA and analgesia. Thus the hypoten-
sive effect of epidural blockade should not be underesti-
mated, especially in hemodynamically unstable patients.
Similar results were obtained by other authors studying
EA in coronary surgery [10,11,28].
A limitation of this patient-controlled mode of analge-
sia is that its use depends on the condition of the
patient. Moreover, some of the effects of PCEA on car-
diopulmonary function occurred transiently and their
clinical significances should be interpreted with caution.
Therefore, larger studies are warranted to confirm our
findings and to determine the optimal regimens of EA
and postoperative analgesia in OPCAB patients.
Conclusion
The use of EA during OPCAB reduces transiently arter-
ial pressure and prevents lung fluid accumulation. Being
a component of a goal-directed perioperative strategy,
the epidural administration of ropivacaine/fentanyl can
improve myocardial performance and provide analgesia
comparable with intravenous opioids, although increas-
ing the requirements for fluids and vasoactive therapies.
After OPCAB, continuous EI combined with PCEA
increases tissue perfusion and improves lung function,
thus shortening the duration of mechanical ventilation.
List of abbreviations
CABG: coronary artery bypass grafting; CI: cardiac index; CFI -cardiac
function index; CO: cardiac output; CPB: cardiopulmonary bypass; CVP:
central venous pressure; dPmax: left ventricle contractility index; EA:
epidural anesthesia; EI: epidural infusion; ECG: electrocardiogram; EVLWI:
extravascular lung water index; FiO2: fraction of inspired oxygen; GEDVI:
global end-diastolic volume index; GEF: global ejection fraction; Hb: blood
hemoglobin concentration; HR: heart rate; ICU: intensive care unit; IV:
intravenously; MAP: mean arterial pressure; OPCAB: off-pump coronary
artery bypass grafting; PaCO2: partial pressure of carbon dioxide in arterial
blood; PaO2: partial pressure of oxygen in arterial blood; PCEA: patient-
controlled epidural analgesia; SpO2: peripheral oxygen saturation; SVRI:
systemic vascular resistance index; VAS: visual analog scale.
Acknowledgements and Funding
The study was presented, in part, at the 21
st Annual Congress of the
European Society of Intensive Care Medicine, Lisbon, Portugal, September
22, 2008, and supported by a grant from the Government of Arkhangelsk
region “Young Pomor scientists” and by departmental funds.
The authors thank Dr. Denis Uvarov, Dr. Vsevolod Kuzkov, Dr. Andrey
Charigin and Dr. Marat Zinurov for their assistance in organizing the study,
and the personnel of the operation theatre and the cardiosurgical ICU, City
Hospital #1 of Arkhangelsk, for their kind help during the conduct of the
investigation.
Author details
1Department of Anesthesiology and Intensive Care Medicine, Northern State
Medical University, Troitsky avenue 51, Arkhangelsk, 163000, Russian
Federation.
2Department of Anesthesiology and Intensive Care Medicine,
City Hospital #1, Suvorov Street 1, Arkhangelsk, 163001, Russian Federation.
3Department of Clinical Medicine (Anesthesiology), Faculty of Medicine,
University of Tromsø, MH-Breivika, Tromsø, 9038, Norway.
4Department of
Anesthesiology, University Hospital of North Norway, Sykehusveien 38,
Tromsø, 9038, Norway.
Authors’ contributions
MYK, AVE and AAS participated in the design of the study, collected and
analyzed the data, prepared figures and tables and drafted the manuscript.
LJB participated in the design of the study and drafted the manuscript. All
authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 April 2011 Accepted: 18 September 2011
Published: 18 September 2011
References
1. Chassot PG, van der Linden P, Zaugg M, Mueller XM, Spahn DR: Off-pump
coronary artery bypass surgery: physiology and anaesthetic
management. Br J Anaesth 2004, 92:400-413.
2. Ngaage DL: Off-pump coronary artery bypass grafting: simple concept
but potentially sublime scientific value. Med Sci Monit 2004, 10:RA47-54.
3. Cheng DCH, Bainbridge D: Fast-track cardiac anesthesia management in
on-pump and off-pump coronary artery bypass surgery. In Perioperative
Care in Cardiac Anesthesia and Surgery. Edited by: Cheng DCH, David TE.
Philadelphia: Lippincott Williams and Wilkins; 2006:59-108.
4. Scott BH, Seifert FC, Grimson R, Glass PS: Resource utilization in on- and
off-pump coronary artery surgery: factors influencing postoperative
length of stay: an experience of 1,746 consecutive patients undergoing
fast-track cardiac anesthesia. J Cardiothorac Vasc Anesth 2005, 19:26-31.
5. Boldt J: Clinical review: Hemodynamic monitoring in the intensive care
unit. Crit Care 2002, 6:52-59.
6. Ngaage DL: Off-pump coronary artery bypass grafting: the myth, the
logic and the science. Eur J Cardiothor Surg 2003, 24:557-570.
Kirov et al. BMC Anesthesiology 2011, 11:17
http://www.biomedcentral.com/1471-2253/11/17
Page 9 of 107. Kessler P, Neidhart G, Lischke V, Bremerich DH, Aybek T, Dogan S, et al:
Coronary bypass operation with complete median sternotomy in awake
patients with high thoracic peridural anesthesia. Anaesthesist 2002,
51:533-538.
8. Nesković V, Milojević P: High thoracic epidural anesthesia in coronary
surgery. Med Pregl 2003, 56:152-156.
9. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative
Cardiac Management in Non-cardiac Surgery of the European Society of
Cardiology (ESC) and endorsed by the European Society of Anaesthesiology
(ESA): Guidelines for pre-operative cardiac risk assessment and
perioperative cardiac management in non-cardiac surgery. Eur J
Anaesthesiol 2010, 27:92-137.
10. Casalino S, Mangia F, Stelian E, Novelli E, Diena M, Tesler U: High thoracic
epidural anesthesia in cardiac surgery. Risk factors for arterial
hypotension. Tex Heart Inst J 2006, 33:148-153.
11. Salvi L, Parolari A, Veglia F, Brambillasca C, Gregu S, Sisillo E: High thoracic
epidural anesthesia in coronary artery bypass surgery: a propensity-
matched study. J Cardiothorac Vasc Anesth 2007, 21:810-815.
12. Scott NB, Turfrey DJ, Ray DA, Nzewi O, Sutcliffe NP, Lal AB, et al: A
prospective randomized study of the potential benefits of thoracic
epidural anesthesia and analgesia in patients undergoing coronary
artery bypass grafting. Anesth Analg 2001, 93:528-535.
13. Sharma M, Mehta Y, Sawhney R, Vats M, Trehan N: Thoracic epidural
analgesia in obese patients with body mass index of more than 30 kg/
m2 for off pump coronary artery bypass surgery. Ann Card Anaesth 2010,
13:28-33.
14. Barrington MJ, Kluger R, Watson R, Scott DA, Harris KJ: Epidural anesthesia
for coronary artery bypass surgery compared with general anesthesia
alone does not reduce biochemical markers of myocardial damage.
Anesth Analg 2005, 100:921-928.
15. Priestley MC, Cope L, Halliwell R, Gibson P, Chard RB, Skinner M, et al:
Thoracic epidural anesthesia for cardiac surgery: the effects on tracheal
intubation time and length of hospital stay. Anesth Analg 2002,
94:275-282.
16. Stenseth R, Bjella L, Berg EM, Christensen O, Levang OW, Gisvold SE: Effects
of thoracic epidural analgesia on pulmonary function after coronary
artery bypass surgery. Eur J Cardiothorac Surg 1996, 10:859-865.
17. Hansdottir V, Philip J, Olsen MF, Eduard C, Houltz E, Ricksten SE: Thoracic
epidural versus intravenous patient-controlled analgesia after cardiac
surgery: a randomized controlled trial on length of hospital stay and
patient-perceived quality of recovery. Anesthesiology 2006, 104:142-151.
18. de Vries AJ, Mariani MA, van der Maaten JM, Loef BG, Lip H: To ventilate or
not after minimally invasive direct coronary artery bypass surgery: the
role of epidural anesthesia. J Cardiothorac Vasc Anesth 2002, 16:21-26.
19. Goepfert MS, Reuter DA, Akyol D, Lamm P, Kilger E, Goetz A: Goal-directed
fluid management reduces vasopressor and catecholamine use in
cardiac surgery patients. Intensive Care Med 2007, 33:96-103.
20. Kirov MY, Lenkin AI, Kuzkov VV, Suborov EV, Slastilin VY, Borodin VV, et al:
Single transpulmonary thermodilution in off-pump coronary artery
bypass grafting: haemodynamic changes and effects of different
anaesthetic techniques. Acta Anaesthesiol Scand 2007, 51:426-433.
21. Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S, et al: Pulmonary
artery occlusion pressure and central venous pressure fail to predict
ventricular filling volume, cardiac performance, or the response to
volume infusion in normal subjects. Crit Care Med 2004, 32:691-699.
22. Hofer CK, Furrer L, Matter-Ensner S, Maloigne M, Klaghofer R, Genoni M,
et al: Volumetric preload measurement by thermodilution: a comparison
with transoesophageal echocardiography. Br J Anaesth 2005, 94:748-755.
23. Pölönen P, Ruokonen E, Hippeläinen M, Pöyhönen M, Takala J: A
prospective, randomized study of goal-oriented hemodynamic therapy
in cardiac surgical patients. Anesth Analg 2000, 90:1052-1059.
24. Smetkin AA, Kirov MY, Kuzkov VV, Lenkin AI, Eremeev AV, Slastilin VY, et al:
Single transpulmonary thermodilution and continuous monitoring of
central venous oxygen saturation during off-pump coronary surgery.
Acta Anaesth Scand 2009, 53:505-514.
25. Lenkutis T, Benetis R, Sirvinskas E, Raliene L, Judickaite L: Effects of epidural
anesthesia on intrathoracic blood volume and extravascular lung water
during on-pump cardiac surgery. Perfusion 2009, 24:243-248.
26. Kiliçkan L, Solak M, Bayindir O: Thoracic epidural anesthesia preserves
myocardial function during intraoperative and postoperative period in
coronary artery bypass grafting operation. J Cardiovasc Surg 2005,
46:559-567.
27. Caputo M, Alwair H, Rogers CA, Ginty M, Monk C, Tomkins S, et al:
Myocardial, inflammatory, and stress responses in off-pump coronary
artery bypass graft surgery with thoracic epidural anesthesia. Ann Thorac
Surg 2009, 87:1119-1126.
28. Tenenbein PK, Debrouwer R, Maguire D, Duke PC, Muirhead B, Enns J, et al:
Thoracic epidural analgesia improves pulmonary function in patients
undergoing cardiac surgery. Can J Anaesth 2008, 55:344-350.
29. Curatolo M: Adding regional analgesia to general anaesthesia: increase
of risk or improved outcome? Eur J Anaesth 2010, 27:586-591.
30. Bakhtiary F, Therapidis P, Dzemali O, Ak K, Ackermann H, Meininger D, et al:
Impact of high thoracic epidural anesthesia on incidence of
perioperative atrial fibrillation in off-pump coronary bypass grafting: a
prospective randomized study. J Thorac Cardiovasc Surg 2007,
134:460-464.
31. Myles PS, McIlroy D: Fast-track cardiac anesthesia: choice of anesthetic
agents and techniques. Semin Cardiothorac Vasc Anesth 2005, 9:5-16.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2253/11/17/prepub
doi:10.1186/1471-2253-11-17
Cite this article as: Kirov et al.: Epidural anesthesia and postoperative
analgesia with ropivacaine and fentanyl in off-pump coronary artery
bypass grafting: a randomized, controlled study. BMC Anesthesiology
2011 11:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kirov et al. BMC Anesthesiology 2011, 11:17
http://www.biomedcentral.com/1471-2253/11/17
Page 10 of 10